Sloan Biotech Fund

MSK Ventures is a dedicated venture capital fund established by Memorial Sloan Kettering Cancer Center. It invests in early-stage life sciences and digital health companies that align with or originate from the institution's pioneering research. The fund’s strategy focuses on deploying capital into high-conviction opportunities to accelerate the development and commercialization of innovative therapies and technologies.

The fund launched in 2026, born from Memorial Sloan Kettering Cancer Center's enduring commitment to translating scientific discoveries into tangible patient benefits. This institutional initiative reflects the insight that direct investment can significantly foster the rapid commercialization of groundbreaking research emerging from one of the world's leading cancer centers.

MSK Ventures primarily serves promising life sciences and digital health startups by providing essential early-stage funding and strategic support. Its long-term vision is to cultivate a more dynamic ecosystem for innovation within Memorial Sloan Kettering, thereby accelerating the translation of scientific breakthroughs into new and effective treatments for patients globally.